Skip to main content
Clinical Trials/NCT03042091
NCT03042091
Unknown
Early Phase 1

Combined Mechanical and Oral Antibiotic Bowel Preparation Versus Oral Antibiotics Alone for the Reduction of Surgical Site Infection Following Elective Colorectal Resection

Thomas Jefferson University1 site in 1 country224 target enrollmentSeptember 2016

Overview

Phase
Early Phase 1
Intervention
Polyethylene Glycol
Conditions
Colorectal Neoplasms
Sponsor
Thomas Jefferson University
Enrollment
224
Locations
1
Primary Endpoint
Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak
Last Updated
7 years ago

Overview

Brief Summary

This randomized clinical trial studies how well neomycin and metronidazole hydrochloride with or without polyethylene glycol work in reducing infection in patients undergoing elective colorectal surgery. Polyethylene glycol, may draw water from the body into the colon, flushing out the contents of the colon. Antibiotics, like neomycin and metronidazole hydrochloride, may stop bacteria from growing. It is not yet known whether it's better to give preoperative neomycin and metronidazole hydrochloride with or without polyethylene glycol in reducing surgical site infection after colorectal surgery.

Detailed Description

PRIMARY OBJECTIVES: I. To estimate the difference in rates of surgical site infection following elective colorectal resections in patients given a preoperative mechanical bowel prep with oral antibiotics as compared to preoperative oral antibiotics alone. SECONDARY OBJECTIVES: I. To determine rates of post-operative clostridium difficile infection, adynamic ileus, cardiopulmonary complications, urinary tract infection, length of stay and mortality in patients given preoperative oral antibiotics with a mechanical bowel prep versus preoperative antibiotics alone.

Registry
clinicaltrials.gov
Start Date
September 2016
End Date
October 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing ileocolic resections, partial and total colectomies, and rectal resections for neoplasm, inflammatory bowel disease, or diverticulitis
  • Subjects with the mental capacity to give informed consent

Exclusion Criteria

  • Patients undergoing emergent colorectal resections
  • Patients who are decisionally-impaired and lack the mental capacity to give informed consent

Arms & Interventions

Arm I (mechanical bowel prep, oral antibiotics)

Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Polyethylene Glycol

Arm I (mechanical bowel prep, oral antibiotics)

Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Neomycin

Arm I (mechanical bowel prep, oral antibiotics)

Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Metronidazole Hydrochloride

Arm I (mechanical bowel prep, oral antibiotics)

Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Therapeutic Conventional Surgery

Arm II (oral antibiotics)

Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Neomycin

Arm II (oral antibiotics)

Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Metronidazole Hydrochloride

Arm II (oral antibiotics)

Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Intervention: Therapeutic Conventional Surgery

Outcomes

Primary Outcomes

Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak

Time Frame: Up to 30 days post operation

The difference in incidence of SSI (antibiotics \[ABX\] - ABX + prep) will be calculated with an upper 95% confidence bound. Exploratory analysis will consider stratum specific estimates of differences in subgroups defined by BMI and diabetes status.

Secondary Outcomes

  • Incidence of adynamic ileus(Up to 30 days post operation)
  • Incidence of cardiopulmonary complications(Up to 30 days post operation)
  • Incidence of urinary tract infection(Up to 30 days post operation)
  • Length of hospital stay(Up to 30 days post operation)
  • Incidence of post-operative clostridium difficile infection(Up to 30 days post operation)
  • Incidence of mortality(Up to 30 days post operation)

Study Sites (1)

Loading locations...

Similar Trials